Regulatory News:
An article with the results of Diamyd Medical's European Phase III study
of the antigen-based diabetes therapy Diamyd® has been published in the
scientific journal the New England Journal of Medicine. The now
published results were previously presented at the American Diabetes
Association’s 71st Scientific Sessions in San Diego, California, USA, on
June 28, 2011.
The title of the published article is “GAD65 Antigen Therapy in Recently
Diagnosed Type 1 Diabetes Mellitus”. The authors are J. Ludvigsson, D.
Krisky, R. Casas, T. Battelino, L. Castaño, J. Greening, O. Kordonouri,
T. Otonkoski, P. Pozzilli, J-J. Robert, H.J. Veeze and J. Palmer.
The article is available via the New England Journal of Medicine’s
website (www.nejm.org),
and will also be published in the printed edition.
Results from Diamyd Medical’s European Phase III study with Diamyd® were
first reported in May 2011. The study did not meet the primary efficacy
endpoint of preserving beta cell function, as measured by
meal-stimulated C-peptide, although a small positive effect was seen.
Safety data from the study showed that Diamyd® was well tolerated, as
demonstrated by a similar number of adverse events reported in the
groups treated with Diamyd® and in the placebo group.
About Diamyd Medical
Diamyd Medical is a Swedish biotech company focusing on the development
of pharmaceuticals for the treatment of pain, neuropathy and diabetes.
The portfolio of development projects for the treatment of chronic pain
and neuropathy uses the Company’s patented NTDDS (Nerve Targeting Drug
Delivery System) platform to administer therapeutic agents directly to
the nervous system. The development project within the area of diabetes
consists of the protein GAD65 for the treatment and prevention of
autoimmune diabetes.
Diamyd Medical has offices in Sweden and in the US. Shares are listed on
Nasdaq OMX (segment Small Cap) in Stockholm (ticker: DIAM B) and on
OTCQX in the US (ticker: DMYDY) administered by the Pink OTC Markets and
the Bank of New York Mellon (PAL). Further information is available on
the Company’s website: www.diamyd.com.
This information is disclosed in accordance with the Swedish Securities
Markets Act, the Swedish Financial Instruments Trading Act, or the
requirements stated in the listing agreements.
Diamyd Medical AB (publ) Karlavägen 108, SE-115 26 Stockholm, Sweden.
Phone: +46 8 661 00 26, Fax: +46 8 661 63 68 E-mail: info@diamyd.com.
Reg. no: 556530-1420
This information was brought to you by Cision http://www.cisionwire.com
